Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 5,905 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: mRI Clear all

Conditions: Multiple Sclerosis
Interventions: Assistive Device Training; Behavioral
Lead sponsor: Portland VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Cancer Screening
Interventions: Contrast-enhanced Spectral Mammography (CESM); Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Glioma
Interventions: Fluorine F 18 Fluorodopa, Intensity-Modulated Radiation Therapy, Positron Emission Tomography; Drug · Radiation · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer
Interventions: Blood collection; Other
Lead sponsor: Angle plc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Bala-Cynwyd, Pennsylvania • Pottstown, Pennsylvania

Conditions: Spasmodic Dysphonia, Singer's Dystonia, Writer's Cramp, Musician's Focal Hand Dystonia, Craniofacial Dystonia, Blepharospasm Oromandibular Dystonia
Interventions: MRI, Blood draw; Other · Procedure
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 21 Years to 80 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stroke, Broca's Aphasia
Interventions: Cortical Electrical Stimulation; Device
Lead sponsor: Northstar Neuroscience; Industry
Eligibility: 21 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Treatment Resistant Depression
Interventions: transcranial magnetic stimulation; Device
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Transgender Women, HIV/AIDS, Cardiovascular Diseases, Metabolic Disease, Coagulopathy
Interventions: Abdominal MR Imaging, Cardiac MRI/MRS, Oral Glucose Tolerance Testing, Whole Body, Lumbar Spine, and Hip DEXA Imaging; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years to 99 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alcohol Use Disorder
Interventions: Intravenous blood draw; Drug
Lead sponsor: Auburn University; Other
Eligibility: 21 Years to 45 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Prostate Adenocarcinoma
Interventions: Computed Tomography, Fluciclovine F18, Gallium Ga68-labeled PSMA-11, Positron Emission Tomography; Procedure · Drug · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Hepatocellular Carcinoma
Interventions: [68Ga]DOTATATE-PET/MRI; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 90 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Tobacco Use Disorder
Interventions: low intensity focused ultrasound (LIFU); Device
Lead sponsor: Washington D.C. Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Small Cell Lung Cancer Extensive Stage, Brain Metastases, Solid Tumor, Adult, Thoracic Cancer, Sarcoma,Soft Tissue, HNPCC
Interventions: Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort C: Sarcoma Pre-Operative PULSAR, Cohort D: Resectable Head & Neck Squamous Cell Carcinoma (HNSCC) PULSAR/SAbR; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Elimusertib, Irinotecan Hydrochloride, Magnetic Resonance Imaging, Topotecan Hydrochloride; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 23
States / cities: Phoenix, Arizona • Orange, California • New Haven, Connecticut + 17 more

Conditions: Oligometastatic Disease
Interventions: 18-F-NaF Cardiac PET/MRI and, CT Angiogram; Diagnostic Test
Lead sponsor: Katelyn Atkins; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: PET Imaging With Cu-64 Labeled Trastuzumab; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions: trastuzumab, aromatase inhibition therapy, carboplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, metabolic assessment, questionnaire administration, study of socioeconomic and demographic variables, cognitive assessment, positron emission tomography, fludeoxyglucose F 18; Biological · Drug · Other + 2 more
Lead sponsor: University of California, San Francisco; Other
Eligibility: 35 Years to 80 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Male Subjects
Interventions: Uridine; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Recurrent Glioblastoma
Interventions: Pembrolizumab, Exablate MRgFUS + neoadjuvant pembolizumab; Drug · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteomyelitis
Interventions: Ferumoxides 11.2Mg Solution for Injection; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Obsessive-Compulsive Disorder, Tic Disorders, Tourette Syndrome
Interventions: Ondansetron, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: New York, New York

Conditions: Unipolar Depression
Interventions: total sleep deprivation, PET imaging; Behavioral · Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 55 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Glioblastoma, Recurrent Glioblastoma, Brain Tumor
Interventions: Troriluzole; Drug
Lead sponsor: Ugonma Chukwueke; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: HIV Infection
Interventions: Adaptive WM CogMed Training, Nonadaptive WM CogMed Training; Other
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years to 85 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Assistive Device Training in Multiple Sclerosis

CESM ABMR Breast Cancer Screening Trial

The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

Brain Networks in Dystonia

Assessment of Cortical Stimulation Combined With Rehabilitation to Enhance Recovery in Broca's Aphasia.

Neuroimaging in Patients Undergoing TMS for Depression

Effects of Gender-Affirming Hormone Therapy Among Transgender Women

Multimodal Neuroimaging of Alcohol Cues, Cortisol Response, and Compulsive Motivation

Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma

Low Intensity Focused Ultrasound for Tobacco Use Disorder: High Resolution Targeting of the Human Insula

Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Real-Time Atherosclerosis Activity After Thoracic Radiotherapy Using Sodium Fluoride Positron Emission Tomography

PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer

Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer

Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Ferumoxytol-enhanced Imaging of Osteomyelitis

Effects of Ondansetron in Obsessive-compulsive and Tic Disorders

The Effects of Sleep Deprivation on Antidepressant Response

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

Neural Correlates of Working Memory Training for HIV Patients